Rebiopsy (bronchoscopy) 16/08/2023 (HP + IHC + Genetic tests: poorly differentiated adenocarcinoma; ALK, EGFR, PD-L1 positive) low expression (TPS = 5%). This evidence concerns the gene EGFR and adenocarcinoma.